Cargando…

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

INTRODUCTION: The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the effect of this agent on cardiometabolic parameters in subjects with T2DM varied in relation to the concomitant prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikolic, Dragana, Patti, Angelo M., Giglio, Rosaria V., Chianetta, Roberta, Castellino, Giuseppa, Magán-Fernández, Antonio, Citarrella, Roberto, Papanas, Nikolaos, Janez, Andrej, Stoian, Anca Pantea, Rizvi, Ali A., Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853434/ https://www.ncbi.nlm.nih.gov/pubmed/35167051 http://dx.doi.org/10.1007/s13300-022-01217-z

Ejemplares similares

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study
por: Terzo, Simona, et al.
Publicado: (2023)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
por: Rizzo, Manfredi, et al.
Publicado: (2016)

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021)

Altilix(®) Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study
por: Castellino, Giuseppa, et al.
Publicado: (2019)

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2023)

Management of Statin Intolerance in 2018: Still More Questions Than Answers
por: Toth, Peter P., et al.
Publicado: (2018)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Rizvi, Ali A., et al.
Publicado: (2021)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

Natural approaches in metabolic syndrome management
por: Patti, Angelo Maria, et al.
Publicado: (2017)

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022)

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021)

Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues
por: Rizvi, Ali A., et al.
Publicado: (2021)

Metabolic disorders during pregnancy and postpartum cardiometabolic risk
por: Patti, Angelo Maria, et al.
Publicado: (2018)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
por: Patti, Angelo M., et al.
Publicado: (2020)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2020)

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact
por: Kapoor, Nitin, et al.
Publicado: (2022)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
por: Rizvi, Ali A., et al.
Publicado: (2021)

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Effects of liraglutide on obesity-associated functional hypogonadism in men
por: Jensterle, M, et al.
Publicado: (2019)

Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study
por: Raimondo, Stefania, et al.
Publicado: (2021)

Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome
por: Freitas, Frederico Perboyre Carioca, et al.
Publicado: (2023)

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
por: Ardeleanu, Valeriu, et al.
Publicado: (2020)

COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)

SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
por: Penlioglou, Theano, et al.
Publicado: (2021)

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
por: Salmen, Teodor, et al.
Publicado: (2023)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
por: Bica, Ioana-Cristina, et al.
Publicado: (2023)

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health
por: Lo Presti, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_539vcf73lijgfrh8fva4qjvdao